Celyad Starts a Third CAR-T Trial, in Metastatic Colorectal Cancer
Celyad has started the SHRINK trial, which will evaluate the synergistic effects of the company’s CAR-T technology in combination with chemotherapy.
After recently reporting impressive 3-month results in colorectal cancer, Celyad has decided to start a third Phase I trial with its CAR-T therapy, which is based on the NKR-2 receptor of natural killer cells and has the potential to target 80% of tumors. This new trial will test whether the immunotherapy can improve efficacy in combination with chemotherapy in patients with metastatic colorectal cancer.
Celyad has already successfully completed a Phase I trial, CM-CS1, in acute myeloid leukemia and multiple myeloma. It is now testing CAR-T NKR2 in another trial (THINK) focusing on five solid tumor types: ovarian, colorectal, pancreas, bladder and triple-negative breast. Confident on the potential of its therapy to treat multiple tumor types, the company plans to start a fourth CAR-T trial, called LINK, in which the engineered cells will be infused via catheter near metastases to increase their concentration in the tumor site.
Image via Juan Gartner / Shutterstock
Let's Continue The Conversation
Feel free to send us comments about this article to firstname.lastname@example.org and/or comment on that article on social media.